Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Acetic acid Clear all
Recruiting Phase 2Phase 3 Interventional

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Navtemadlin, Navtemadlin Placebo
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Vallejo, California • Atlanta, Georgia • Savannah, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Daily Vinegar Ingestion and Metabolic Health

NCT05698381
View directory record Official record
Conditions
Inflammation, Metabolic Syndrome, Depression
Interventions
Liquid vinegar, Vinegar pill
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 17, 2026, 9:59 PM EDT
Withdrawn Not applicable Interventional

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

NCT00980551
View directory record Official record
Conditions
Retinoblastoma
Interventions
subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 9:59 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Apple Cider Vinegar Supplementation on 24-hour Urine Chemistry in Adults

NCT07389226
View directory record Official record
Conditions
Kidney Stones, Urine Specimen Collection
Interventions
Apple Cider Vinegar
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 9:59 PM EDT
Not listed Phase 1Phase 2 Interventional

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

NCT04640532
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Interventions
KRT-232, TL-895
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Whittier, California • Lake City, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

NCT00551148
View directory record Official record
Conditions
Primary Insomnia
Interventions
PD 0200390, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phenoix, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT04450693
View directory record Official record
Conditions
Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions
TTAX01, Standard care
Biological · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
16
States / cities
Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 17, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

NCT00532311
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 17, 2026, 9:59 PM EDT
Not listed Phase 2Phase 3 Interventional

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

NCT03662126
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions
KRT-232, Best Available Therapy (BAT)
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 17, 2026, 9:59 PM EDT
Terminated Not applicable Interventional

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

NCT04001855
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Dilute vinegar (acetic acid), Dilute bleach
Other
Lead sponsor
University of Arizona
Other
Eligibility
5 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Cetirizine, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of Poppi Apple Cider Vinegar Prebiotic Soda to Improve Gut Health In Participants

NCT05418439
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Drink Poppi Soda
Dietary Supplement
Lead sponsor
Drink Poppi
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Results available

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

NCT03217266
View directory record Official record
Conditions
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Interventions
Navtemadlin, Radiation Therapy, Surgical Procedure
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
53
States / cities
Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311
View directory record Official record
Conditions
Alopecia
Interventions
Setipiprant, Placebo, Finasteride
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

NCT00655369
View directory record Official record
Conditions
Nonrestorative Sleep
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
52
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT00773955
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
R-(-)-gossypol acetic acid, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 17, 2026, 9:59 PM EDT
Completed No phase listed Observational

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

NCT00890448
View directory record Official record
Conditions
Toxicity
Interventions
Pharmacogenomic whole blood sampling
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Jacksonville, Florida • Jupiter, Florida • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 17, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

NCT01290380
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
ASA404, DMXAA, DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

NCT00848016
View directory record Official record
Conditions
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions
R-(-)-gossypol acetic acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 17, 2026, 9:59 PM EDT
Terminated Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions
KRT-232, Cytarabine, Decitabine
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 17, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

NCT04312841
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
Interventions
Letermovir
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 17, 2026, 9:59 PM EDT
Terminated Phase 1Phase 2 Interventional

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197
View directory record Official record
Conditions
Locally Advanced Esophageal or GE Junction Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 17, 2026, 9:59 PM EDT